Medicine Pricing
The price of
medicines are controlled to varying degrees by the Indian government. We aren’t
the only country that regulates the prices of various medicines. I had assumed
this is a practice of poorer countries only.
Not true, I learnt
as I read Alex Tabarrok’s post. But first, why do pharma companies (including Western giants
with political clout) agree to such reduced pricing? Because of the nature of
their product – coming up with a new medicine is very, very costly (research,
clinical trials, regulatory clearances, making doctors aware). But the
manufacturing cost of each pill in and of itself is very tiny (in most cases).
Therein lies the answer to our question.
“Not
because firms are charitable, but because a high price means poorer countries
buy nothing, while any price above marginal cost is still profit.”
Thus:
“This
type of price discrimination is good for poorer countries, good for pharma, and
(indirectly) good for the United States: more profits mean more R&D and,
over time, more drugs.”
As healthcare
totters in the US, more and more Americans ask why they pay more for the same
medicine that is sold cheaper elsewhere (including Europe).
“Riding
that grievance, Trump has demanded that U.S. prices be no higher than
the lowest level paid in other developed countries.”
How could this
play out?
Option 1 is pharma companies increase prices
worldover, their profits increase, they spend more on R&D to find newer
cures. In this scenario, medicine prices in the US don’t/won’t come down by
much (since prices are raised everywhere to US-comparable levels).
Option 2 is most countries refuse to pay more.
Already Switzerland indicayed they would rather ration and switch to off-patent
generics. In this case, pharma profits decline, R&D spending reduces, and
US prices don’t drop much.
The article
doesn’t talk of Option 3, which to me esp. in a world that
dislikes Trump so intensely is a real possibility. Countries may decide to
produce their own medicines or more likely, show a willingness to switch to
non-American options. European countries would be best placed to come up with
new pharma giants of the future. China and many emerging economies would also
enter the fray in certain areas. Who can really bet against some of them
succeeding?
All systems are complicated. Changing them is fraught with risks of second and third order consequences. Things could end up worse than before. Any such changes require a thought-out and phased approach, but the largest economy on the planet doesn’t have any of those characteristics nowadays.
Comments
Post a Comment